New Jersey Clinic Opens to Offer Ketamine Therapy for Depression, PTSD

A South Plainfield ketamine clinic that opened April 4 is offering supervised infusions to patients who have cycled through multiple antidepressants without relief, placing New Jersey inside a fast-growing psychiatric treatment sector that regulators have yet to govern with any consistent national standard.

The clinic targets treatment-resistant depression, PTSD and related mood disorders through infusions paired with psychological support. Providers built in cardiac screening, infusion-phase monitoring and mandatory follow-up as baseline safety requirements. "We've seen profound responses in patients who had exhausted other options," one clinician said, stressing that all treatment is delivered under medical supervision with built-in safety checks.

The clinical evidence base for ketamine therapies splits along regulatory lines. Esketamine, the S-enantiomer of ketamine sold as Spravato, received FDA and EMA approval for treatment-resistant depression in 2019. Johnson & Johnson subsequently won supplemental FDA approval showing Spravato alone produced rapid and superior improvement in depressive symptoms compared to placebo in as little as 24 hours. That clearance was announced in January 2025. Intravenous ketamine carries no FDA mental health indication; its optimal dosing schedules and maintenance protocols remain subjects of active research, leaving the off-label infusion market to operate in a regulatory gray zone.

That asymmetry drives a significant cost gap for patients. Because IV ketamine is not FDA-approved for mental health conditions, insurers typically label it "experimental" or "investigational." An initial course of six to eight infusions typically runs $2,400 to $6,400 without insurance, compared to potentially $300 to $3,200 for Spravato with adequate coverage. Medicare covers 80 percent of Spravato costs once the annual Part B deductible is met. A handful of private insurers have begun breaking from the standard exclusion: Blue Cross Blue Shield of Massachusetts has a policy covering IV ketamine for depression, but such arrangements remain uncommon nationwide.

State rules governing clinic operations vary just as widely. Licensing boards determine who may administer ketamine, with some states permitting nurse practitioners with specialized training to oversee infusions while others require direct physician supervision. New York and California require comprehensive licensure frameworks and rigorous health department checks before a clinic can legally operate. States with more permissive scope-of-practice laws, like Arizona, provide less restrictive requirements, giving practitioners considerably more flexibility. No federal body sets a universal credentialing floor for ketamine operators. New Jersey's stricter compounding pharmacy regulations carry higher operational costs than many other states, and in-clinic IV infusion fees in New Jersey typically run $500 to $900 per session.

On December 31, 2025, the DEA, in coordination with the Department of Health and Human Services, published a fourth temporary extension of COVID-era telemedicine flexibilities for controlled-substance prescribing, preserving the ability to prescribe ketamine remotely through the end of 2026. Critics argue the provision makes enforcing in-person oversight standards harder to sustain as clinic volume grows.

Professional societies hold that any reputable ketamine provider should meet a consistent baseline regardless of state. Good protocols include pre-session vital sign checks, real-time oversight from licensed clinicians, clear emergency procedures, and guidance on when to seek immediate medical attention. Legitimate clinics document every milligram dispensed and maintain consent forms, dosing records and adverse-event reports. Comprehensive care extends beyond individual sessions through integration therapy and scheduled follow-ups.

For patients evaluating a provider, the checklist should include verifying the prescribing physician's board certification and DEA registration, asking explicitly what protocols exist if a dissociative episode occurs during infusion, confirming whether integration therapy is offered on-site or referred out, and settling all cost and coverage questions before a first appointment.

The South Plainfield clinic's opening adds another entry to a ledger that state health departments and federal agencies have yet to reconcile into coherent national policy. The pace at which new providers are entering the market is, at present, faster than the pace at which oversight frameworks are being written.